Details

Autor(en) / Beteiligte

• Heidegger, Isabel
• Massoner, Petra
• Eder, Iris E.
• Pircher, Andreas
• Pichler, Renate
• Aigner, Friedrich
• Bektic, Jasmin
• Horninger, Wolfgang
• Klocker, Helmut

Titel

Novel therapeutic approaches for the treatment of castration-resistant prostate cancer

Ist Teil von

• The Journal of steroid biochemistry and molecular biology, 2013-11, Vol.138, p.248-256

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2013

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• •New drugs approved for treatment of castration resistant prostate cancer.•Prime targets: androgen receptor, bone cells, cell division, immune system.•Several promising drugs disappointed in clinical trials.•Further efforts necessary to optimize the sequence and combinations of drugs.•New biomarkers required for stratification of patient and therapy selection. Prostate cancer is a leading cause of cancer death in men in developed countries. Once the tumor has achieved a castration-refractory metastatic stage, treatment options are limited with the average survival of patients ranging from two to three years only. Recently, new drugs for treatment of castration-resistant prostate cancer (CRPC) have been approved, and others are in an advanced stage of clinical testing. In this review we provide an overview of the new therapeutic agents that arrived in the clinical praxis or are tested in clinical studies and their mode of action including hormone synthesis inhibitors, new androgen receptor blockers, bone targeting and antiangiogenic agents, endothelin receptor antagonists, growth factor inhibitors, novel radiotherapeutics and taxanes, and immunotherapeutic approaches. Results and limitations from clinical studies as well as future needs for improvement of CRPC treatments are critically discussed.